×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. We are committed to safeguarding your information and ensuring the highest standards of data protection. Your trust and privacy are of utmost importance to us.

Cardioprotection in Type 2 Diabetes Mellitus

  1955 Views

Dr Pramila Kalra, Bengaluru    14 December 2021

  • The burden of cardiovascular disease (CVD) is very high in India. The risk is increased 2 to 4 times if an adult has diabetes mellitus.
  • Women with diabetes seem to lose their inherent protection against CVD.
  • The time to occurrence of the first MACE is shorter in South Asians compared to Europeans.
  • This is a continuum, starting from before prediabetes sets in and progresses further as type 2 diabetes develops.
  • The treatment for the prevention of CVD should be started early in patients with diabetes.
  • The drugs like SGLT2 inhibitors have multiple beneficial effects on CV and renal outcomes.
  • ADA 2021 recommends that among patients with type 2 diabetes who have established ASCVD or indicators of high-risk, established kidney disease or heart failure, SGLT2 inhibitors or GLP-1 receptor agonists with demonstrated CV benefits should be given.
  • The treatment should be initiated early to get the maximum benefit.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.